Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Neogen Corporation

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services, Inc.

Neogen provides solutions for food and animal safety, self-described as serving these sectors.

Metric
Company Name	Neogen Corporation	West Pharmaceutical Services, Inc.
Symbol	NEOG	WST
MSH ID	COM:NEOGEN	COM:WESTPHARMA
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Medical - Diagnostics & Research	Medical - Instruments & Supplies
Country	US	US
Stage
Employee Count	2.64K	10.60K
Website	neogen.com	westpharma.com
LinkedIn
Founders

Metric
Market Cap	3.29B	23.41B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	924.22M	2.95B
Revenue (LTM)
Revenue (NTM)
Gross Profit	462.63M	1.13B
EBITDA	198.65M	875.70M
Operating Income	77.43M	676M
Net Income	-9.42M	593.40M
EPS	-0.04	7.98
Diluted EPS	-0.04	7.88
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.51	0.38
Operating Profit Margin	0.07	0.23
EBITDA Margin	0.21	0.30
Net Profit Margin	0.01	0.20
Return on Equity	0.00	0.21
Return on Assets	0.00	0.16
Return on Capital Employed	0.02	0.22

COM:NEOGEN

Neogen

Last Close

14.58

22/11 21:00

Market Cap

3.29B

Beta: -

Volume Today

1.10M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	277.96	52.81
P/B Ratio	1.04	10.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.12	9.76
EV Multiple	19.55	34.90

Metric
Days Sales Outstanding	59.79	64.74
Days Payables Outstanding	90.19	44.24
Days Inventory Outstanding	159.31	87.15
Operating Cycle	226.38	150.56
Cash Conversion Cycle	177.08	104.66
Asset Turnover	0.20	0.82

Metric
Operating Cash Flow	34.73M	776.50M
Free Cash Flow	-76.69M	414.50M
Cash Flow to Debt	0.13	3.31
Operating Cash Flow/Sales	0.12	0.26
Free Cash Flow Yield	0.01	0.01

Metric
Cash & Equivalents	170.61M	853.90M
Accounts Receivable	-20.10M	4M
Inventory	189.27M	434.70M
Goodwill	2.14B	108.50M
Debt to Capitalization	0.22	0.10
Debt to Assets	0.19	0.08
Current Ratio	3.54	3.70
Quick Ratio	2.79	2.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.01
R&D to Revenue	0.03	0.02
SG&A to Revenue	0.21